Prospective nanoparticle treatments for lymphangioleiomyomatosis.

Emelie LandhRoger WangLyn M MoirDaniela TrainiPaul M YoungHui Xin Ong

Published in: Expert opinion on drug delivery (2022)

Advanced clinical research is still needed to demonstrate the full potential and drive future commercialization of LAM treatments delivered via inhaled lipid nanobased formulations. If successful, the resultant effects will be seen in the improvement in the life expectancy and life quality of LAM patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
cystic fibrosis
peritoneal dialysis
prognostic factors
quality improvement
climate change
human health
patient reported